Age: 73.0
Sex: F
Vaccine: COVID19
Symptoms: Arthropathy, Asthenia, Cough, Dizziness, Feeling abnormal
Clinical narrative: More vertigo than before; weak-knees buckling.; brain fog/ HAZY MIND; dry tongue; dizzy; weakness/difficulty standing up; cough; This spontaneous case was reported by a consumer and describes the occurrence of ARTHROPATHY (weak-knees buckling.), FEELING ABNORMAL (brain fog/ HAZY MIND), TONGUE DRY (dry tongue), DIZZINESS (dizzy) and ASTHENIA (weakness/difficulty standing up) in a 73-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 032B21A and 024A21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included Sinus infection (get these infections every winter), Bronchitis asthmatic on 02-Apr-2020, Pneumonia, Vertigo in October 2017 and Sinusitis from 22-Mar-2021 to April 2021. Previously administered products included for Infection: ANTIBIOTICS. Concurrent medical conditions included Allergy NOS (Ccocky , sneezy, environmental allergy since 1990.) and Pollen allergy. Concomitant products included HYDROCHLOROTHIAZIDE for Elevated BP, ASCORBIC ACID, COPPER GLUCONATE, TOCOPHERYL ACID SUCCINATE, XANTOFYL, ZEAXANTHIN, ZINC OXIDE (AREDS 2 VISUAL ADVANTAGE) for Macular degeneration, CETIRIZINE HYDROCHLORIDE (ZYRTEC [CETIRIZINE HYDROCHLORIDE]), FLUTICASONE PROPIONATE (FLONASE [FLUTICASONE PROPIONATE]), ALBUTEROL SULFATE and AZELASTINE for an unknown indication.   On 05-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 03-Apr-2021, the patient experienced ARTHROPATHY (weak-knees buckling.), FEELING ABNORMAL (brain fog/ HAZY MIND), TONGUE DRY (dry tongue), DIZZINESS (dizzy), ASTHENIA (weakness/difficulty standing up) and COUGH (cough). On an unknown date, the patient experienced VERTIGO (More vertigo than before). The patient was treated with FLUTICASONE PROPIONATE (FLONASE [FLUTICASONE PROPIONATE]) for Antihistamine therapy, at an unspecified dose and frequency. On 16-May-2021, ARTHROPATHY (weak-knees buckling.), FEELING ABNORMAL (brain fog/ HAZY MIND), TONGUE DRY (dry tongue), ASTHENIA (weakness/difficulty standing up) and COUGH (cough) had resolved. At the time of the report, DIZZINESS (dizzy) and VERTIGO (More vertigo than before) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 27-Mar-2021, SARS-CoV-2 test: negative (Negative) Negative. On 28-Mar-2021, Magnetic resonance imaging: abnormal (abnormal) punctate foci of cerebral white matter T2/ Flair Hypersensitivity, appearance non specific but may reflect mild to moderate chronic microangiopathic changes. Rest MRI normal..         Treatment medications include Steroids.   This case was linked to MOD-2021-139676 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 28-Jul-2021: Patient demographic, Medical history, Lab data, Concomitant medications, treatment medications added. Events outcome updated.